Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppression in uveitis.

Ali R Djalilian1, Robert B Nussenblatt

  • 1National Eye Institute, National Institutes of Health, 10 Center Drive, Building 10, Room 10N112, Bethesda, MD 20892, USA.

Ophthalmology Clinics of North America
|November 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contact Lens-Associated Ocular Surface and Corneal Disorders.

Methods and protocols·2026
Same author

Evaluation of the Potential of a Fast-Curing Polymer Bioadhesive Hydrogel for Corneal Defect Repair.

Gels (Basel, Switzerland)·2026
Same author

Amniotic membrane in ophthalmology: Historical perspectives, biological properties, and clinical applications.

Progress in retinal and eye research·2026
Same author

Cereblon enhances hepatic hepcidin production through estrogen-related receptor gamma activation.

BMB reports·2026
Same author

Current and Developing Therapeutics for Dry Eye Disease: Targeting Ion Channels.

Current issues in molecular biology·2026
Same author

Clinical evidence on allogeneic blood-derived eye drops in ocular surface and corneal diseases.

The ocular surface·2026
Same journal

Contrast sensitivity and measuring cataract outcomes.

Ophthalmology clinics of North America·2006
Same journal

Capsular tension rings: update on endocapsular support devices.

Ophthalmology clinics of North America·2006
Same journal

Management of vitreous loss and dropped nucleus during cataract surgery.

Ophthalmology clinics of North America·2006
Same journal

Astigmatism control.

Ophthalmology clinics of North America·2006
Same journal

New technology IOL optics.

Ophthalmology clinics of North America·2006
Same journal

Phaco fluidics and phaco ultrasound power modulations.

Ophthalmology clinics of North America·2006
See all related articles

Treating ocular inflammatory disease is challenging. Biologic agents offer a promising, targeted approach for immunosuppression, but long-term studies are needed to confirm their role in uveitis treatment.

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Ocular inflammatory diseases present complex treatment challenges.
  • Current therapies like corticosteroids, antimetabolites, and calcineurin inhibitors carry significant risks and benefits.
  • Balancing immunosuppression efficacy with patient safety remains a clinical hurdle.

Purpose of the Study:

  • To explore novel therapeutic strategies for ocular inflammatory conditions.
  • To evaluate the potential of biologically active agents as a safer, more targeted immunosuppressive option.
  • To highlight the need for further research into biologic agents for uveitis management.

Main Methods:

  • Review of current immunosuppressive therapies for ocular inflammation.
  • Discussion of the mechanisms and potential benefits of biologic agents, including monoclonal antibodies.

Related Experiment Videos

  • Emphasis on the necessity of long-term clinical studies.

    • Main Results:

    • Biologic agents represent a promising advancement in targeted immunosuppression.
    • These agents offer the potential for more specific immune system modulation compared to traditional therapies.
    • Current data suggests a favorable safety profile, but requires long-term validation.

    Conclusions:

    • Biologic agents, such as monoclonal antibodies, show significant promise for treating ocular inflammatory diseases.
    • They offer a more targeted and potentially safer alternative to conventional immunosuppressants.
    • Further long-term research is crucial to establish the definitive role of biologic agents in uveitis treatment.